OINDPnews


Aptar Pharma banner

Medical

Sunovion partners with CHEST for “Delivery Makes a Difference” initiative

Sunovion Pharmaceuticals and the American College of Chest Physicians (CHEST) have launched an initiative called "Delivery Makes a Difference," which they say "seeks to understand patient and health care provider practices and to provide tools for matching patients with appropriate medications and delivery devices." According to the announcement, a steering … [Read more...] about Sunovion partners with CHEST for “Delivery Makes a Difference” initiative

Mylan and Theravance announce positive Phase 3 results for inhaled revefenacin for COPD

Theravance Biopharma and Mylan have announced that two 12-week Phase 3 efficacy studies of nebulized revefenacin (TD-4208) for the treatment of COPD have met their primary efficacy endpoint of statistically significant increase in FEV1 for both doses studied compared to placebo. Patients receiving the 88 mcg dose averaged a 118 mL increase in tough FEV1 after 12 weeks … [Read more...] about Mylan and Theravance announce positive Phase 3 results for inhaled revefenacin for COPD

Aradigm and Woolcock Institute of Medical Research get grant for development of aerosol nanotechnology

Aradigm Corporation has partnered with Professors Daniela Traini and Paul Young of the University of Sydney's Woolcock Institute of Medical Research to develop an aerosol nanoparticle technology to combat fungal and bacterial biofilms. The project will be funded by a A$420,000 grant from an Australian Research Council Linkage Project over three years. According to … [Read more...] about Aradigm and Woolcock Institute of Medical Research get grant for development of aerosol nanotechnology

Sumatriptan nasal spray shortage expected to be resolved by February 2017

According to an FDA drug shortages report, the US shortage of sumatriptan nasal spray due to a shortage of active ingredient that was first reported in November 2015 should be completely resolved by February 2017. At this time, both GlaxoSmithKline and Sandoz are reported to have 5 mg/spray versions of the nasal spray available, and GSK has the 20 mg product … [Read more...] about Sumatriptan nasal spray shortage expected to be resolved by February 2017

Positive Phase 2 results for Patara’s inhaled treatment for chronic cough in IPF patients

Patara Pharma has announced Phase 2 results for its PA101 inhaled treatment for refractory chronic cough in patients with idiopathic pulmonary fibrosis (IPF) showing that patients receiving PA101 experienced a statistically significant reduction in cough frequency after 14 days compared to patients receiving a placebo. PA101 is delivered via the PARI eFlow nebulizer … [Read more...] about Positive Phase 2 results for Patara’s inhaled treatment for chronic cough in IPF patients

Flutiform fails to meet primary endpoint in Phase 3 trial for COPD

According to Vectura, Mundipharma's Phase 3 trial of the flutiform fluticasone/formoterol MDI failed to demonstrate statistically significant superiority compared to formoterol alone in reducing moderate and severe COPD exacerbations. Mundipharma had planned to seek approval from European regulators to market flutiform for the treatment of COPD but will now put off … [Read more...] about Flutiform fails to meet primary endpoint in Phase 3 trial for COPD

Paradigm Biopharmaceuticals completes Phase 1 trial of pentosan polysulfate sodium nasal spray

Paradigm Biopharmaceuticals has announced the completion of a Phase 1 clinical trial of its Rhinosul pentosan polysulfate sodium (PPS) nasal spray for allergic rhinitis. Paradigm said that none of the 18 healthy volunteers involved in the study experienced any significant adverse effects and that it anticipates the final report in October 2016. The company also … [Read more...] about Paradigm Biopharmaceuticals completes Phase 1 trial of pentosan polysulfate sodium nasal spray

AstraZeneca announces positive results from two Symbicort studies

AstraZeneca has announced top-line results from the Phase 3 RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) and CHASE 3 (ChildHood Asthma Safety and Efficacy) studies of the Symbicort budesonide/formoterol fumarate MDI showing that Symbicort met the primary endpoints in both studies. The RISE study compared twice daily Symbicort MDI … [Read more...] about AstraZeneca announces positive results from two Symbicort studies

Windtree gets $2.6 million for Phase 2b trial of Aerosurf

Windtree Therapeutics has received $1 million from a Phase 2 Small Business Innovation Research Grant (SBIR) worth up to $2.6 million for a Phase 2b trial of its Aerosurf aerosolized KL4 surfactant in premature infants with respiratory distress syndrome (RDS) who are receiving nasal continuous positive airway pressure (nCPAP). The company previously received a … [Read more...] about Windtree gets $2.6 million for Phase 2b trial of Aerosurf